A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

NCT06764186 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Breast Cancer

Interventions

DRUG: Fulvestrant
DRUG: Capivasertib

Sponsor

AstraZeneca

Collaborators

Apices Soluciones S.L.
SOLTI Breast Cancer Research Group